Clinical Trial Update: Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating chemotherapy de-escalation in HR-positive, HER2-negative intermediate-risk early breast cancer treated with adjuvant ribo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• KISQALI (ribociclib)

Snippet

Sponsor: UNICANCER | Conditions: Breast Cancer | Phase 3 | Status: RECRUITING